A widely used Alzheimer’s drug may finally have given up its biggest secret. Researchers have shown that lecanemab – an antibody therapy designed to remove amyloid plaques – works not just by binding these toxic deposits, but by activating the brain’s immune cells through a specific structural component known as the Fc fragment. The finding helps resolve long-standing uncertainty around how anti-amyloid therapies exert their effects, and could reshape the design of next-generation treatments.
In a series of experiments using a mouse model populated with human microglia, the team demonstrated that the Fc portion of the antibody acts as a molecular “switch.” While one end of lecanemab binds amyloid plaques, the Fc fragment engages receptors on microglia, triggering these cells to engulf and degrade the deposits. When this fragment was disabled, the antibody still attached to plaques – but crucially failed to induce any clearance, providing direct evidence that microglial activation is essential for therapeutic efficacy.
Further analysis using single-cell and spatial transcriptomics revealed that lecanemab induces a specific microglial gene expression program linked to phagocytosis, lysosomal degradation, and metabolic reprogramming. Among the most strongly upregulated genes was SPP1, which encodes osteopontin, a protein shown to actively promote plaque clearance. These molecular changes were concentrated in microglia located near amyloid plaques, suggesting a highly localized and targeted immune response rather than widespread inflammation.
Importantly, the study also found that this activation does not appear to trigger harmful side effects such as excessive synapse loss – an issue associated with some earlier antibody therapies. Instead, microglia selectively removed amyloid while preserving surrounding neural structures, and reductions in plaque burden were accompanied by decreases in neuritic damage. This more controlled immune activation may help explain why lecanemab shows modest but measurable clinical benefits compared with other anti-amyloid antibodies.
Despite these advances, key challenges remain. The same Fc-mediated immune engagement that drives plaque clearance may also contribute to adverse effects, such as inflammation or vascular complications, which are difficult to capture fully in current models. The authors suggest that fine-tuning Fc interactions – or bypassing antibodies altogether by directly stimulating microglial pathways – could offer safer, more effective strategies.
By pinpointing the mechanism behind one of the field’s most closely watched therapies, the work provides a clearer blueprint for Alzheimer’s drug development – shifting the focus from simply targeting amyloid to precisely controlling how the brain’s immune system responds.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
